SING SEATTLE, WA--(Marketwired - Nov 24, 2015) -
SING SEATTLE, WA--(Marketwired - Nov 24, 2015) - SinglePoint, Inc. (OTC: SING) announces today great strides in its previously announced sports fantasy roll up acquisition strategy. SinglePoint has received tremendous response from Sports Fantasy Groups since the announcement last week that Sports guru Darren Heitner and his Dynasty Dealings are working with SinglePoint to identify and negotiate acquisition targets in the Daily Fantasy Sports (DFS) sector toward an overall roll up merger.
In addition, every candidate SinglePoint has been introduced to is interested in the Company's proprietary pay-by-text and processing capabilities.
Dynasty is a Sports Consulting company that works to revolutionize the sports and entertainment industries and it has already secured advanced discussions with a potential acquisition target with which SinglePoint now has an NDA and initial terms toward a win-win negotiation.
Lambrecht comments, "We couldn't be more impressed with Darren's influence and reach in this unique sector. It was our hope to secure tangible targets in the near term, but within the first week has exceeded our own expectations. I'm thrilled with the prospect of shareholders owning a piece of this world. SinglePoint's mobile technology is a perfect match for the sports fantasy industry. We are cultivating something here toward exponential shareholder value in a sector I believe is both exciting and profitable."
Recent legislative moves, such as the Cease and Desist by New York Attorney General to multi-million dollar companies DraftKings and FanDuel have caused some to wonder about the viability of the industry, but the SinglePoint Board of Directors are confident that though this may end up affecting a handful of states, it's nothing but good news in regards to the roll up strategy.
"Companies are looking for alternatives, flexibility," states Lambrecht. "Moving the companies into a public entity like SinglePoint gives them the upside in an exit strategy many may be seeking and this is reflected in our conversations with acquisition candidates. I am confident that DFS will continue to thrive legally and the Board is willing to make that bet accordingly toward increased shareholder value. The data capture in DFS membership information alone will be a worthwhile asset for SinglePoint regardless of the overall future of the industry."
Many bills propose to allow DFS to be under the oversight of the State Gaming Commissions, such as Senator Michael Ranzenhofer's bill in New York, which seeks to exempt DFS from the Gambling Code.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...
Continue Reading
Top 5 Most Recently Viewed Articles
Equitage Ventures Launches Significant Investment Fund Equitage Ventures, an early-stage venture capital firm dedicated to AgeTech, has announced the successful final closing of a substantial $47.3 million investment fund. This fund is designed to provide critical capital, distribution resources, and strategic guidance to innovative entrepreneurs who aim to tackle the...
Continue Reading
Chevron Corp Market Sentiment Analysis Chevron Corp (NYSE: CVX) has experienced a noteworthy decline in its short interest as a percentage of float, showing a 10.26% decrease since its previous report. Currently, there are approximately 14.02 million shares sold short, which accounts for 0.7% of all shares available for trading. Given the trading volume, it is estimated...
Continue Reading
Introducing the Blakely McCrory Hope Fund Moody Gardens is proud to announce a special initiative to honor the memory of a young girl who captured the hearts of many: the Blakely McCrory Hope Fund. This fund has been established in loving memory of 8-year-old Blakely McCrory, who lost her life in a tragic flooding incident that occurred during the summer months....
Continue Reading
Exciting Holiday Table Read for a Worthy Cause The Ed Asner Family Center is pulling out all the stops this holiday season with an exciting virtual table read of the beloved classic, "It's a Wonderful Life." Scheduled for December 14 at 5 PM PST, this event promises to spread joy while supporting individuals and families with special needs. Star-Studded Cast Comes...
Continue Reading
Understanding the Growth of Monolithic Power Systems Monolithic Power Systems (NASDAQ: MPWR) has showcased impressive financial performance over the past decade, outperforming many market benchmarks. With an impressive annualized growth rate of 19.88%, it has attracted the attention of savvy investors. The Power of Compounded Returns Imagine investing $100 in MPWR stock...
Continue Reading